Each 1 ml contains:
Clindamycin 150 mg (as clindamycin phosphate 178.3 mg)

Solution for injection

Clindamycin is effective in the treatment of the following infections caused by susceptible anaerobic bacteria or susceptible gram-positive aerobic bacteria such as streptococci, staphylococci, pneumococci, and susceptible strains of Chlamydia trachomatis.
(a) Upper respiratory tract infections including tonsillitis, pharyngitis, sinusitis, otitis media, and scarlet fever.
(b) Lower respiratory tract infections including bronchitis, pneumonia, empyema, and lung abscess.
(c) Skin and soft tissue infections including acne, furuncles, cellulitis, impetigo, abscesses, and wound infections. Specific skin and soft tissue infections such as erysipelas and paronychia (panaritium) respond well to treatment with clindamycin.
(d) Bone and joint infections including osteomyelitis and septic arthritis
(e) Gynecological infections including endometritis, cellulitis, bacterial vaginosis, tubo-ovarian abscess, salpingitis and pelvic inflammatory disease when combined with an appropriate aerobic gram-negative antibacterial agent. In the case of cervicitis due to Chlamydia trachomatis, treatment with clindamycin alone has been found to be effective in eradicating the organism.
(f) Intra-abdominal infections including peritonitis and intra-abdominal abscess when combined with an appropriate aerobic gram-negative antibacterial agent.
(g) Bacteremia and endocarditis - the efficacy of clindamycin has been documented in the treatment of selected cases of endocarditis when clindamycin has been shown to be effective in killing the infecting organism in vitro at adequate serum concentrations.
(h) Dental infections such as periodontal abscesses and periodontitis
(i) Toxoplasmosis in AIDS patients. In patients intolerant of conventional therapy, clindamycin in combination with pyrimethamine has been found to be effective.
(j) Pneumocystis jirovecii pneumonia (formerly classified as Pneumocystis carinii) in AIDS patients. In patients intolerant of or inadequately responsive to conventional therapy, clindamycin may be used in combination with primaquine.
(k) Prophylaxis of endocarditis in patients hypersensitive/allergic to penicillin(s).
(l) Prophylaxis of infection in head and neck surgery. Clindamycin phosphate dissolved in saline is a solution
used for irrigating surgical wounds.

Clindamycin phosphate, when used concurrently with an aminoglycoside antibiotic such as gentamycin or tobramycin, has been shown to be effective in preventing peritonitis or intra-abdominal abscesses following intestinal perforation and secondary bacterial infections following trauma.
In vitro, microorganisms susceptible to clindamycin include: B. melaninogenicus, B. disiens, B. bivius, Peptost
reptococcus spp., G. vaginalis, M. mulieris, M. curtisii and Mycoplasma hominis

Clindamycin phosphate for intramuscular injection should be administered undiluted.
Clindamycin phosphate for intravenous infusion should be administered diluted.